Gena Lee Meyers
Business Development Lead Curocell
Gena is the Head of BD at Curocell, a commercial-stage CAR-T cell therapy company. With prior experience as a scientist at Kite Pharma in process development, she leads global partnerships and expansion efforts by combining expertise in CMC, technology transfer, and business development. Gena actively drives co-development and licensing collaborations to advance next-generation cell therapies and expand Curocell’s global presence.
Seminars
Wednesday 11th November 2026
Translating Domestic CAR-T Innovation Into Global Competitiveness: Insights From Korea’s First BLA Approval
9:00 am
- Unveiling the process and strategy in obtaining first domestic CAR-T therapy in Korea
- Sharing the commercialization and expansion plan for approved CAR-T therapy
- Outlining future development plans
Wednesday 11th November 2026
Korean & Global Leaders Fireside Panel: Reviewing the Current Cell & Gene Therapy Landscape Towards Developing Scalable & Efficacious Drugs to Combat Cancer, Autoimmune Diseases & Beyond
11:30 am
Hear from executive leaders who will discuss their ambitions, strategies and challenges for the future cell and gene therapies, the hottest indications of unmet need and progress towards the next commercial approval, which include:
- What are the future opportunities, promising targets and applications on the horizon for cell and gene therapies to achieve clinical success?
- What are the current industry’s top priorities and upcoming hurdles to development, such as investment, manufacturing, pricing and reimbursement and commercialization to better prepare and strategize to navigate the evolving landscape
- How to structure successful biotech–pharma–academia collaborations in South Korea to balance expectations and maximize the translational speed of your CAR-T, gene editing and therapeutic programs
